Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
Stracke H, Lindemann A, Federlin K. Stracke H, et al. Among authors: lindemann a. Exp Clin Endocrinol Diabetes. 1996;104(4):311-6. doi: 10.1055/s-0029-1211460. Exp Clin Endocrinol Diabetes. 1996. PMID: 8886748 Clinical Trial.
In a double-blind, randomized, controlled study, the effectiveness of treatment with a combination of Benfotiamine (an Allithiamine, a lipid-soluble derivative of vitamin B1 with high bioavailability) plus vitamin B6/B12 on objective parameters of neuropathy …
In a double-blind, randomized, controlled study, the effectiveness of treatment with a combination of Benfotiamine (an Allithi …
Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer HP, Mertelsmann R. Oster W, et al. Among authors: lindemann a. J Clin Oncol. 1990 Jun;8(6):956-62. doi: 10.1200/JCO.1990.8.6.956. J Clin Oncol. 1990. PMID: 2189957 Clinical Trial.
None of the patients had a history of bleeding, hemolysis, renal insufficiency, or other disorders causing anemia in addition to bone marrow infiltrating malignancy. ...Five patients (one MM, four small-cell lymphocytic [SCLC] NHL) showed a dramatic increase of hemo …
None of the patients had a history of bleeding, hemolysis, renal insufficiency, or other disorders causing anemia in addition to bone …
Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia.
Herrmann F, Helfrich SG, Lindemann A, Schleiermacher E, Huber C, Mertelsmann R. Herrmann F, et al. Among authors: lindemann a. J Clin Oncol. 1992 Apr;10(4):631-4. doi: 10.1200/JCO.1992.10.4.631. J Clin Oncol. 1992. PMID: 1548526
A complete or partial hematologic remission was achieved in the remaining six patients, of whom two patients experienced a complete cytogenetic response. ...CONCLUSION: These findings indicate that circulating levels of TNF are increased in a subset of patien
A complete or partial hematologic remission was achieved in the remaining six patients, of whom two patients experienced a com
Biologic effects of recombinant human interleukin-3 in vivo.
Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R. Lindemann A, et al. J Clin Oncol. 1991 Dec;9(12):2120-7. doi: 10.1200/JCO.1991.9.12.2120. J Clin Oncol. 1991. PMID: 1960553 Clinical Trial.
The biologic in vivo effects of recombinant human interleukin-3 (rhIL-3) were assessed in a phase I clinical study of 30 patients with advanced malignancy. ...The results indicate that rhIL-3 acts in vivo as a multilineage hematopoietic growth factor and a we …
The biologic in vivo effects of recombinant human interleukin-3 (rhIL-3) were assessed in a phase I clinical study of 30 patients wit …
GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).
Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, et al. Heil G, et al. Among authors: lindemann a. Leukemia. 1995 Jan;9(1):3-9. Leukemia. 1995. PMID: 7845026 Clinical Trial.
The probability of relapse-free survival at 41 months after a median follow-up of 35 months was 42% in the GM-CSF and 41% in the placebo group (p = 0.89; log rank test). ...For the present GM-CSF does not have a significant effect on treatment outcome....
The probability of relapse-free survival at 41 months after a median follow-up of 35 months was 42% in the GM-CSF and 41% in the plac …
Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2.
Lindemann A, Brossart P, Höffken K, Flasshove M, Voliotis D, Diehl V, Kulmburg P, Wagner H, Mertelsmann R. Lindemann A, et al. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):225-30. doi: 10.1097/00002371-199404000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8032546 Clinical Trial.
This was evaluated in a phase-Ib study with ultra-low-dose IL-2 at 0.9 and 4.5 MIU/m2 administered once daily subcutaneously either once weekly (4 doses, stratum I), three times a week every other day (9 doses, stratum II), or five times a week every other we …
This was evaluated in a phase-Ib study with ultra-low-dose IL-2 at 0.9 and 4.5 MIU/m2 administered once daily subcutaneously either o …
Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R. Herrmann F, et al. Among authors: lindemann a. J Clin Oncol. 1989 Feb;7(2):159-67. doi: 10.1200/JCO.1989.7.2.159. J Clin Oncol. 1989. PMID: 2644395
The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. ...Administration of rh GM-CSF resulted in a broad spectrum of dose- and …
The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 pa …
Erythropoietin prevents chemotherapy-induced anemia: case report.
Oster W, Herrmann F, Cicco A, Gamm H, Zeile G, Brune T, Lindemann A, Schulz G, Mertelsmann R. Oster W, et al. Among authors: lindemann a. Blut. 1990 Feb;60(2):88-92. doi: 10.1007/BF01720513. Blut. 1990. PMID: 2405925 Clinical Trial.
EPO was discontinued after 9 weeks of administration when the patient had achieved a hematocrit (HCT) of 41.1% and a HB of 12.7 g/dl. However, erythropoiesis continued to recover for the next 7 weeks reaching a HCT of 42.4% and a HB of 14.3 g/dl, altho …
EPO was discontinued after 9 weeks of administration when the patient had achieved a hematocrit (HCT) of 41.1% and a HB of 12. …
Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha.
Herrmann F, Gebauer G, Lindemann A, Brach M, Mertelsmann R. Herrmann F, et al. Among authors: lindemann a. Clin Exp Immunol. 1989 Jul;77(1):97-100. Clin Exp Immunol. 1989. PMID: 2504521 Free PMC article.
Following incubation of monocyte subsets in the presence or absence of IFN-gamma and IL-2 for a culture period of 24-48 h, cell-free culture supernatants were collected and assayed for IL-1 beta and TNF-alpha activity by ELISA. ...
Following incubation of monocyte subsets in the presence or absence of IFN-gamma and IL-2 for a culture period of 24-48 h, cell-free …
MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Oster W, Forsthuber T, Hennekeuser HH, Gamm H, Lindemann A, Schmitz G, Fuhr HG, Hinterberger R, Kreiter H, Thoenes W, et al. Oster W, et al. Among authors: lindemann a. Blut. 1990 Jan;60(1):23-7. doi: 10.1007/BF01720198. Blut. 1990. PMID: 1688725
Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. ...At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL …
Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP …
201 results
Jump to page
Feedback